According to a recent LinkedIn post from Techstars, Munich-based healthtech startup dehaze, part of the Techstars 2025 cohort, has raised €3.2M in new funding. The post indicates that dehaze is developing foundational causal AI tools aimed at early detection of chronic diseases by analyzing large volumes of patient data for healthcare payers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s platform is described as helping insurers and other payers identify at-risk individuals sooner, improve intervention outcomes, and reduce costs. The LinkedIn post notes that the capital will be used to expand technical and commercial teams and to advance capabilities such as next-best-action recommendations and improved traceability.
A quote from dehaze CEO and co-founder Marius Klages in the post suggests management is positioning the firm as a potential category-defining player in chronic disease detection, with an emphasis on a global customer base from inception. For investors in Techstars’ portfolio, this early-stage financing round and focus on scalable AI-driven cost reduction in healthcare could signal long-term optionality in a large, structurally growing market.
The emphasis on payer adoption speed, as mentioned in the post, may imply early commercial traction, though no specific customer metrics or revenue figures are provided. If dehaze can convert current interest into recurring contracts and successfully scale its AI platform, the development could enhance Techstars’ exposure to value-based care trends and reinforce its positioning in the European healthtech and AI ecosystems.